Alcon Inc. - Registered Shares
ALC
Market Cap$42.24B
Close$
Earnings Call Q1 2025
May 14, 2025 - AI Summary
Sales Performance and Growth Forecast: Alcon reported first quarter sales of $2.5 billion, reflecting a 3% growth year-over-year. However, the company has tempered its full-year sales growth guidance to between 6% and 7% in constant currency, down from previous estimates, largely due to softness in the U.S. surgical market.
Product Launches and Innovations: The company is optimistic about several upcoming product launches, primarily Unity VCS and PanOptix Pro, which are expected to drive significant sales growth in the second half of 2025. They anticipate a revenue acceleration, particularly with new product rollouts and expect high-single-digit growth in the back half of the year.
Challenges in the U.S. Surgical Market: Alcon continues to face challenges within the U.S. surgical market, primarily attributed to an ongoing slowdown in procedures and competition from other companies, which has led to a downgrade in their growth expectations for the cataract market.
Exclusive for Stockcircle Pro members
Sign up
$30.14
65.4% downside
Current Fair Value
65.4% downsideOvervalued by 65.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $42.24 Billion |
|---|---|
| Enterprise Value | $46.15 Billion |
| Dividend Yield | $0.3334 (0.3903981264637%) |
| Earnings per Share | $2.06 |
| Beta | 0.7 |
| Outstanding Shares | 495,100,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 37.75 |
|---|---|
| PEG | 91.79 |
| Price to Sales | 4.36 |
| Price to Book Ratio | 1.98 |
| Enterprise Value to Revenue | 4.64 |
| Enterprise Value to EBIT | 30.4 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Alcon, Inc.
20,000 employees
CEO: David J. Endicott Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the followi...